Diamonds and Dogs


Guess (GES) not guessing anymore. The clothing retailer is up 24% following better than expected earnings and raised guidance for the year. Guess is still struggling in the Americas, but it's offsetting its domestic sales declines with robust growth in Asia and Europe. CEO Victor Herrero confidently declared, "This year marks the beginning of a turnaround for the company."

AbbVie (ABBV) taking a hit. The biotech company is down 12% as the company will not accelerate approval of a lung cancer drug based on phase 2 trial results. AbbVie said it does still believe the drug also called Rova-T, has potential in small cell lung cancer and other cancers expressing the DLL3 protein, and Rova-T continues to be studied in ongoing phase 3 trials for first-line and second-line small cell lung cancer. AbbVie bought Rova-T in a $5.8 billion deal for Stemcentrx in 2016; Rova-T was the company's lead asset.

Diamonds and Dogs market commentary is a journal of daily observations on anything that happens to be of interest to our author. Obviously, our primary focus is the stock market and world economic events, but for this page we have no defined topics. We want this page to be dedicated to the interests, concerns, and possibly to the financial gain of our clients and friends. All comments contained herein are for informational purposes only, and should not be considered as a solicitation to buy or sell any security. The firm does not guarantee the accuracy or completeness of the information or make any warranties regarding results from it's usage.